Magdalena Del Rocío Sevilla-González1,2,3,4,5, Jordi Merino2,4,6, Hortensia Moreno-Macias7, Rosalba Rojas-Martínez8, Donají Verónica Gómez-Velasco5, Alisa K Manning9,10,11. 1. Clinical and Translational Epidemiology Unit, Massachusetts General Hospital, 100 Cambridge, Boston, MA, USA. 2. Programs in Metabolism and Medical & Population Genetics, Broad Institute of MIT and Harvard, Cambridge, MA, USA. 3. Doctoral Program in Health Sciences, Universidad Nacional Autonóma de México, Mexico City, Mexico. 4. Department of Medicine, Harvard Medical School, Boston, MA, USA. 5. Unidad de Investigacion en Enfermedades Metabolicas, Insituto Nacional de Ciencias Medicas y Nutricion "Salvador Zubiran", Mexico City, Mexico. 6. Diabetes Unit and Center for Genomic Medicine, Massachusetts General Hospital, Boston, MA, USA. 7. Universidad Autonoma Metropolitana, Mexico City, Mexico. 8. Insitituto Nacional de Salud Publica, Mexico City, Mexico. 9. Clinical and Translational Epidemiology Unit, Massachusetts General Hospital, 100 Cambridge, Boston, MA, USA. akmanning@mgh.harvard.edu. 10. Programs in Metabolism and Medical & Population Genetics, Broad Institute of MIT and Harvard, Cambridge, MA, USA. akmanning@mgh.harvard.edu. 11. Department of Medicine, Harvard Medical School, Boston, MA, USA. akmanning@mgh.harvard.edu.
Abstract
BACKGROUND: Impaired fasting glucose (IFG) is a prevalent and potentially reversible intermediate stage leading to type 2 diabetes that increases risk for cardiometabolic complications. The identification of clinical and molecular factors associated with the reversal, or regression, from IFG to a normoglycemia state would enable more efficient cardiovascular risk reduction strategies. The aim of this study was to identify clinical and biological predictors of regression to normoglycemia in a non-European population characterized by high rates of type 2 diabetes. METHODS: We conducted a prospective, population-based study among 9637 Mexican individuals using clinical features and plasma metabolites. Among them, 491 subjects were classified as IFG, defined as fasting glucose between 100 and 125 mg/dL at baseline. Regression to normoglycemia was defined by fasting glucose less than 100 mg/dL in the follow-up visit. Plasma metabolites were profiled by Nuclear Magnetic Resonance. Multivariable cox regression models were used to examine the associations of clinical and metabolomic factors with regression to normoglycemia. We assessed the predictive capability of models that included clinical factors alone and models that included clinical factors and prioritized metabolites. RESULTS: During a median follow-up period of 2.5 years, 22.6% of participants (n = 111) regressed to normoglycemia, and 29.5% progressed to type 2 diabetes (n = 145). The multivariate adjusted relative risk of regression to normoglycemia was 1.10 (95% confidence interval [CI] 1.25 to 1.32) per 10 years of age increase, 0.94 (95% CI 0.91-0.98) per 1 SD increase in BMI, and 0.91 (95% CI 0.88-0.95) per 1 SD increase in fasting glucose. A model including information from age, fasting glucose, and BMI showed a good prediction of regression to normoglycemia (AUC = 0.73 (95% CI 0.66-0.78). The improvement after adding information from prioritized metabolites (TG in large HDL, albumin, and citrate) was non-significant (AUC = 0.74 (95% CI 0.68-0.80), p value = 0.485). CONCLUSION: In individuals with IFG, information from three clinical variables easily obtained in the clinical setting showed a good prediction of regression to normoglycemia beyond metabolomic features. Our findings can serve to inform and design future cardiovascular prevention strategies.
BACKGROUND:Impaired fasting glucose (IFG) is a prevalent and potentially reversible intermediate stage leading to type 2 diabetes that increases risk for cardiometabolic complications. The identification of clinical and molecular factors associated with the reversal, or regression, from IFG to a normoglycemia state would enable more efficient cardiovascular risk reduction strategies. The aim of this study was to identify clinical and biological predictors of regression to normoglycemia in a non-European population characterized by high rates of type 2 diabetes. METHODS: We conducted a prospective, population-based study among 9637 Mexican individuals using clinical features and plasma metabolites. Among them, 491 subjects were classified as IFG, defined as fasting glucose between 100 and 125 mg/dL at baseline. Regression to normoglycemia was defined by fasting glucose less than 100 mg/dL in the follow-up visit. Plasma metabolites were profiled by Nuclear Magnetic Resonance. Multivariable cox regression models were used to examine the associations of clinical and metabolomic factors with regression to normoglycemia. We assessed the predictive capability of models that included clinical factors alone and models that included clinical factors and prioritized metabolites. RESULTS: During a median follow-up period of 2.5 years, 22.6% of participants (n = 111) regressed to normoglycemia, and 29.5% progressed to type 2 diabetes (n = 145). The multivariate adjusted relative risk of regression to normoglycemia was 1.10 (95% confidence interval [CI] 1.25 to 1.32) per 10 years of age increase, 0.94 (95% CI 0.91-0.98) per 1 SD increase in BMI, and 0.91 (95% CI 0.88-0.95) per 1 SD increase in fasting glucose. A model including information from age, fasting glucose, and BMI showed a good prediction of regression to normoglycemia (AUC = 0.73 (95% CI 0.66-0.78). The improvement after adding information from prioritized metabolites (TG in large HDL, albumin, and citrate) was non-significant (AUC = 0.74 (95% CI 0.68-0.80), p value = 0.485). CONCLUSION: In individuals with IFG, information from three clinical variables easily obtained in the clinical setting showed a good prediction of regression to normoglycemia beyond metabolomic features. Our findings can serve to inform and design future cardiovascular prevention strategies.
Entities:
Keywords:
Cardiometabolic risk; Dysglycemia; Metabolomics; Regression to normoglycemia
Authors: Amy L Williams; Suzanne B R Jacobs; Hortensia Moreno-Macías; Alicia Huerta-Chagoya; Claire Churchhouse; Carla Márquez-Luna; Humberto García-Ortíz; María José Gómez-Vázquez; Noël P Burtt; Carlos A Aguilar-Salinas; Clicerio González-Villalpando; Jose C Florez; Lorena Orozco; Christopher A Haiman; Teresa Tusié-Luna; David Altshuler Journal: Nature Date: 2013-12-25 Impact factor: 49.962
Authors: Yingxu Zeng; Asanda Mtintsilana; Julia H Goedecke; Lisa K Micklesfield; Tommy Olsson; Elin Chorell Journal: Metabolism Date: 2019-04-04 Impact factor: 8.694
Authors: Rury R Holman; Sanjoy K Paul; M Angelyn Bethel; H Andrew W Neil; David R Matthews Journal: N Engl J Med Date: 2008-09-10 Impact factor: 91.245
Authors: Alexis C Frazier-Wood; Ani Manichaikul; Stella Aslibekyan; Ingrid B Borecki; David C Goff; Paul N Hopkins; Chao-Qiang Lai; Jose M Ordovas; Wendy S Post; Stephen S Rich; Michèle M Sale; David Siscovick; Robert J Straka; Hemant K Tiwari; Michael Y Tsai; Jerome I Rotter; Donna K Arnett Journal: Hum Genet Date: 2012-12-22 Impact factor: 4.132
Authors: Magdalena Del Rocio Sevilla-Gonzalez; Alisa K Manning; Kenneth E Westerman; Carlos Alberto Aguilar-Salinas; Amy Deik; Clary B Clish Journal: BMJ Open Diabetes Res Care Date: 2022-10
Authors: Parag Anilkumar Chevli; Barry I Freedman; Fang-Chi Hsu; Jianzhao Xu; Megan E Rudock; Lijun Ma; John S Parks; Nicholette D Palmer; Michael D Shapiro Journal: Cardiovasc Diabetol Date: 2021-12-07 Impact factor: 8.949